| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8859551 | GALDERMA LABS LP | Compounds, formulations, and methods for treating or preventing inflammatory skin disorders |
May, 2024
(7 months from now) | |
| US8231885 | GALDERMA LABS LP | Compounds, formulations, and methods for ameliorating telangiectasis |
May, 2025
(1 year, 7 months from now) | |
| US8410102 | GALDERMA LABS LP | Methods and compositions for treating or preventing erythema |
May, 2025
(1 year, 7 months from now) | |
| US8426410 | GALDERMA LABS LP | Compounds, formulations, and methods for treating or preventing inflammatory skin disorders |
May, 2025
(1 year, 7 months from now) | |
| US7439241 | GALDERMA LABS LP | Compounds, formulations, and methods for treating or preventing rosacea |
Aug, 2025
(1 year, 10 months from now) | |
| US8513249 | GALDERMA LABS LP | Methods and compositions for safe and effective treatment of erythema |
Mar, 2031
(7 years from now) | |
| US9861631 | GALDERMA LABS LP | Methods and compositions for safe and effective treatment of erythema |
Mar, 2031
(7 years from now) | |
| US9861632 | GALDERMA LABS LP | Methods and compositions for safe and effective treatment of erythema |
Mar, 2031
(7 years from now) | |
| US8513247 | GALDERMA LABS LP | Methods and compositions for safe and effective treatment of erythema |
Mar, 2031
(7 years from now) | |
| US8163725 | GALDERMA LABS LP | Gel compositions and methods of use |
Jun, 2031
(7 years from now) | |
| US8053427 | GALDERMA LABS LP | Brimonidine gel composition |
Jun, 2031
(7 years from now) | |
| US10201517 | GALDERMA LABS LP | Brimonidine gel compositions and methods of use |
Jun, 2031
(7 years from now) | |
Mirvaso is owned by Galderma Labs Lp.
Mirvaso contains Brimonidine Tartrate.
Mirvaso has a total of 12 drug patents out of which 0 drug patents have expired.
Mirvaso was authorised for market use on 23 August, 2013.
Mirvaso is available in gel;topical dosage forms.
Mirvaso can be used as topical treatment of facial erythema of rosacea.
The generics of Mirvaso are possible to be released after 13 June, 2031.
Drugs and Companies using BRIMONIDINE TARTRATE ingredient
Market Authorisation Date: 23 August, 2013
Treatment: Topical treatment of facial erythema of rosacea
Dosage: GEL;TOPICAL
MIRVASO family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic